Freedom Broker Issues Pessimistic Forecast for INmune Bio (NASDAQ:INMB) Stock Price

INmune Bio (NASDAQ:INMB) had its target price decreased by analysts at Freedom Broker from $4.00 to $2.50 in a research note issued to investors on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock. Freedom Broker‘s price target points to a potential upside of 138.10% from the company’s previous close.

A number of other equities analysts have also recently commented on INMB. Wall Street Zen cut shares of INmune Bio from a “hold” rating to a “sell” rating in a research report on Saturday, November 7th. Weiss Ratings raised shares of INmune Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $2.50.

INmune Bio Price Performance

Shares of NASDAQ INMB remained flat at $1.05 during midday trading on Friday. The stock had a trading volume of 476,498 shares, compared to its average volume of 275,200. INmune Bio has a one year low of $1.01 and a one year high of $2.60. The business has a 50 day moving average of $1.76 and a 200 day moving average of $1.61. The company has a market capitalization of $32.51 million, a price-to-earnings ratio of -1.75 and a beta of 0.97.

INmune Bio (NASDAQ:INMB) last posted its earnings results on Thursday, November 5th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02).

Institutional Trading of INmune Bio

Several institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP bought a new position in INmune Bio during the third quarter worth about $176,000. Russell Investments Group Ltd. raised its stake in INmune Bio by 64.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 25,246 shares of the company’s stock worth $49,000 after purchasing an additional 9,850 shares in the last quarter. Ieq Capital LLC acquired a new stake in INmune Bio in the 2nd quarter worth about $134,000. BlackRock Inc. acquired a new stake in INmune Bio in the 2nd quarter worth about $508,000. Finally, Bank of New York Mellon Corp bought a new stake in INmune Bio in the 2nd quarter valued at about $35,000. 12.72% of the stock is currently owned by institutional investors.

About INmune Bio

INmune Bio, Inc. is a clinical-stage biotechnology company developing treatments that target the innate immune system. The company’s research focuses on using immune responses to address cancer and inflammatory conditions, including neuroinflammation. Its pipeline includes XPro1595, a selective inhibitor of soluble tumor necrosis factor being studied for conditions including Alzheimer’s disease, and INKmune, an investigational cell therapy designed to enhance natural killer cell activity against cancer.